

BMB Reports – Manuscript Submission

Manuscript Draft

Manuscript Number: BMB-19-142

Title: Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation

Article Type: Mini Review

Keywords: Parkinson's disease; hiPSC; alpha-synuclein; aggregation; disease modeling

Corresponding Author: Yohan Oh

Authors: Yohan Oh^{1,*}

Institution: ¹Department of Medicine, College of Medicine and ²Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea,

Manuscript Type: Mini Review

Title: Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation

Author's name: Yohan Oh

Affiliation: ¹Department of Medicine, College of Medicine, ²Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Korea

Running Title: None

Keywords: Parkinson's disease, hiPSC, alpha-synuclein, aggregation, disease modeling

Corresponding Author's Information: Tel.: +82-2-2220-2423; E-mail: yoh@hanyang.ac.kr

ABSTRACT

After the first research declaring the generation of human induced pluripotent stem cells (hiPSCs) in 2007, several attempts have been made to model neurodegenerative disease *in vitro* during the past decade. Parkinson's disease (PD) is the second most common neurodegenerative disorder, which is mainly characterized by motor dysfunction. The formation of unique and filamentous inclusion bodies called Lewy bodies (LBs) is the hallmark of both PD and dementia with LBs. The key pathology in PD is generally considered to be the alpha-synuclein (α -syn) accumulation, although it is still controversial whether this protein aggregation is a cause or consequence of neurodegeneration. In the present work, the recently published researches which recapitulated the α -syn aggregation phenomena in sporadic and familial PD hiPSC models were reviewed. Furthermore, the advantages and potentials of using patient-derived PD hiPSC with focus on α -syn aggregation have been discussed.

INTRODUCTION

Parkinson's disease (PD) is a progressive, age-related neurodegenerative disease with noteworthy motor impairments, and is the second most common neurodegenerative disease after Alzheimer's disease (AD). PD is primarily linked with the explicit loss of midbrain dopaminergic (mDA) neurons in the substantia nigra pars compacta (SNpc), and it physically displays as weakened movements in affected individuals (1, 2). The formation of unique and filamentous inclusion bodies called Lewy bodies (LBs), comprised mostly of alpha-synuclein (α -syn, *SNCA* gene product), is considered as the hallmark of PD or dementia with LBs (DLB) (1-6). Although the key pathology in PD or DLB is commonly known to be the accumulation of misfolded- and aggregated- α -syn (2-7), the formation of pathological α -syn aggregates is not typically displayed in general neurotoxin-based PD animal models (8, 9). In addition, several trials for PD drugs continue to fail; this leads to a significant socioeconomic burden on our healthcare system and emphasizes the need for a new approach to model PD pathogenesis.

Human pluripotent stem cells (hPSCs), including embryonic stem or induced pluripotent stem cells (hESCs/hiPSCs), differentiated into specific types of neurons have emerged as a promising model for studying human neural diseases (10-14) and have the potential to be used as cell sources for transplantation (15, 16). Particularly, disease-specific hiPSCs provide us with an exceptional opportunity to recapitulate human disease phenotypes *in vitro*, thereby enabling disease investigation and drug development; although there are several challenges which need to be addressed [reviewed in (17)]. Using PD patients' hiPSCs, many researchers have tested whether PD-relevant phenotypes are reproduced in the patient-derived mDA neurons *in vitro* to reveal PD pathology and to identify therapeutic targets; however, abnormally phosphorylated detergent-insoluble α -syn aggregates are rarely recapitulated in these model systems [reviewed in (18, 19)].

In this review, it was investigated whether the α -syn aggregation phenomena in PD or DLB can be reproduced in hiPSC-based models, the present extent of development, and the type of further researches necessitated in future.

α -Synuclein aggregation and α -synucleinopathy

At the time of initial cloning, α -syn was called as the ‘precursor of non-A β component of AD amyloid’ (precursor of NAC, NACP) because the NAC was first detected in and isolated from AD amyloid plaques (20). α -Syn protein is a soluble protein and exists in the form of an unfolded monomer (21). Furthermore, it has been considered that α -syn undergoes a conformational change to the α -helical structure only upon binding to lipid vesicles (22). As unstructured α -syn monomers tend to eagerly undergo a conformational change to β -sheet structure and aggregate together, it has been hypothesized that binding of lipid vesicles with the α -helical conformation of α -syn monomers is a crucial intrinsic mechanism for sequestering unfolded cytosolic α -syn to prevent spontaneous α -syn aggregation. However, recent studies indicate that α -syn exists in the form of an α -helically folded tetramer in the physiological conditions and not as a natively unfolded monomer, and rarely this tetramer is converted into the pathological aggregates (23, 24). The PD missense mutations located in the lipid-binding motif of α -syn increase the transition from tetramer to monomer (25), by the formation of β -sheet oligomers and eventually as insoluble aggregates in pathological conditions. A growing number of evidence indicates a causative role of α -syn misfolding and aggregation in the pathogenesis of PD (2-7, 26, 27). α -Synucleinopathies (also called synucleinopathies) are neurodegenerative diseases representing the abnormal accumulation of intracellular aggregates of α -syn in neurons (LB and Lewy neurite) or glial cells (28). Among α -synucleinopathies, PD, DLB, and multiple system atrophy (MSA) are of the most common

occurrence. The incident rate of α -synucleinopathies related to parkinsonism was 21.0 per 100,000 person-years (PD, 68% of α -synucleinopathies; DLB, 28%; MSA, 4%), based on the investigation of the medical records in Olmsted County, Minnesota, USA, 1991-2005 (29). Classical neurotoxin-based animal models do not model the molecular pathology of α -synucleinopathies (8, 9). However, many attempts have been made to recapitulate α -synucleinopathies in the mammalian system using α -syn transgenic mouse models, viral vector models of α -syn overexpression, and α -syn transmission models [reviewed in (9)].

Phosphorylation of α -synuclein

Phosphorylation is the most widely and deeply studied posttranslational modification of α -syn. This modification may affect the ability of aggregate formation as well as the subcellular localization and function of α -syn. In recent years, an increasing number of studies have reported that α -syn within LBs is subjected to phosphorylation at serine 129 (S129), and it may have serious implications for α -syn-induced neurodegeneration (7, 30-34). Especially, S129-phosphorylated α -syn (pS129- α -syn) is an excellent marker for α -synucleinopathies because ~90% of α -syn in LBs is phosphorylated at S129, compared with only ~4% of α -syn under physiological conditions (7). However, the molecular and cellular mechanisms of α -syn aggregation controlled by phosphorylation and other effects of α -syn phosphorylation at S129, remain to be elucidated (35, 36), probably due to a lack of a pathophysiologically relevant model system for investigating α -syn aggregation of α -synucleinopathies. Therefore, it should be clearly addressed whether α -syn phosphorylation is a cause or a consequence of aggregation, or whether phosphorylation is neurotoxic or neuroprotective in α -synucleinopathies including PD and DLB.

Human pluripotent stem cell-derived midbrain dopaminergic neurons

Developing the most ideal protocol for human mDA neuronal differentiation from hPSCs for applications in PD modeling and/or transplantation therapy has been an intense area of research during the past decade. Arenas et al. have reviewed the molecular mechanisms underlying mDA neuronal development *in vivo* and their applications for *in vitro* generation of human mDA neurons differentiated from hPSCs or directly induced from somatic cells [reviewed in (37)]. In this section, popular and major protocols for the human mDA neuronal differentiation from hPSCs are briefly introduced (**Figure 1**).

Stromal feeder-induced midbrain dopaminergic neurons

The classical approach to developing a protocol for the human mDA neuronal differentiation from hPSCs was based on adaptations of mouse neural stem cell (mNSC) and mESC protocols, which required co-culture with feeder cells (37). Three groups have published the initial protocols to derive mDA neurons from hESCs co-cultured with the murine stromal cell lines (38-40). In 2007, Sonntag et al. reported an enhanced protocol to generate neural rosette-derived mDA neurons from hESCs co-cultured with the MS-5 cells as a feeder, appropriate for cell therapy in PD (41) (**Figure 1A**).

Embryonic body-derived midbrain dopaminergic neurons

For initiating spontaneous differentiation from hPSC towards specific cell types, embryonic body (EB)-formation is often considered as a basic starting method. After inducing EB-formation, putative mDA neurons are generated from hESCs (42, 43). In 2009, Swistowski et al. published a protocol to derive expandable mDA progenitors and mDA neurons from hESCs *via* EB-formation and neural rosette-isolation (44) (**Figure 1B**).

Floor plate-derived midbrain dopaminergic neurons

Studer group introduced a “dual-SMAD inhibition” method for differentiating hPSCs into neural cells in an exceedingly efficient manner to eliminate the influence of undefined factors, including unknown secreted molecules and unidentified effects of co-culturing with murine stromal cell lines or astrocytes, as well as to increase the efficiency and to reduce heterogenous nature on neuronal differentiation (45). Combined blockage of SMAD signaling at the beginning of the monolayer differentiation protocol using Noggin (to inhibit BMP-mediated SMAD signaling) and SB431542 (to inhibit TGF- β /nodal/activin-mediated SMAD signaling), synergistically facilitated neural induction of hPSCs and eliminated the need for feeder layers (45).

The developing midbrain co-expresses the roof plate marker LMX1A and the floor plate (FP) marker FOXA2. Administration of high levels of SHH along with the dual-SMAD inhibition during neural induction has been considered as essential for FP specification (46). By synthesizing the existing knowledge of midbrain development, Studer group succeeded in generating correctly specified hPSC-derived mDA neurons in a reliable and efficient manner (47). A follow-up study has described the use of a small molecule, LDN193189 (to inhibit BMP-mediated SMAD signaling), that can replace Noggin for neural induction of hPSCs (48). Modified dual SMAD inhibition (termed “LSB” for two inhibitors LDN193189 and SB431542) along with activation of SHH and WNT signaling, enhances the efficiency and reproducibility of the monolayer differentiation of hPSC-derived mDA neurons *via* FP-induction.

Genetic models using patient-derived human induced pluripotent stem cell

Jaenisch group reported the first example of PD modeling using PD patient-derived hiPSC-based DA neurons in 2009, but the focus of the study did not cover the phenotypical differences between patient’s cells and healthy controls (49). After the pioneer study, many

groups attempted to model PD *in vitro* using patient hiPSC-derived neuronal cells and reported various *in vitro* phenotypes consistent with PD pathophysiology [reviewed in (18, 19)]. While tons of studies failed to repeat the aggregation of α -syn in PD hiPSC-based models, a handful of researches recapitulated α -syn aggregation in PD patient-derived hiPSC-based neuronal models by employing unique conditions (**Table 1**). It is necessary to state that cases showing simple augmentation of α -syn expression were intentionally omitted in the present review.

Sporadic PD hiPSC-based model

The causes of sporadic PD and DLB are largely unknown; however, the aggregation of α -syn is heavily implicated in the degeneration of neurons in sporadic PD and DLB (50). In 2016, Krainc group reported the detection of the thioflavin S-positive α -syn aggregates in the FP-derived 110 days old mDA neurons, which were differentiated from a sporadic PD hiPSC (51). The authors also showed that the level of pathogenic α -syn species detected by Syn303 antibody (52) was significantly increased in the 1% Triton X-100-insoluble-and-2% SDS-soluble fraction of the sporadic PD mDA neurons, as compared to healthy controls (51). Another report described the increased level of pS129- α -syn in the FP-derived 28-49 days old mDA neurons differentiated from a sporadic PD hiPSC, although the authors did not assess the formation of α -syn aggregates in these neurons (53).

Familial PD hiPSC-based model: SCNA mutations

Mutations in *SCNA* (also known as *PARK1* and *PARK4*) gene, which encodes α -syn, lead to autosomal dominant PD (1). The thioflavin S-positive and proteinase K-resistant α -syn aggregates were detected in the EB-derived 50 days old neurons differentiated from a familial PD hiPSC with a point mutation in *SNCA* gene (c.[157G>A];[=]/p.[Ala53Thr];[=], also

known as heterozygous A53T) (54). Moreover, the level of pS129- α -syn was increased in the A53T neurons (54). Ryan *et al.* also reported an increase in thioflavin T-positive or Ser129-phosphorylated α -syn aggregates formation and ROS production in the FP-derived 35 days old A53T mDA neurons, as compared to genetically corrected controls (55). The authors have further revealed the susceptibility of A53T mDA neurons to apoptosis induced by environmental pesticides, such as paraquat, maneb, and rotenone, compared to the controls (55). The presence of thioflavin S-positive α -syn aggregates in the FP-derived 90 days old A53T mDA neurons has been demonstrated along with the reduction in aggregate formation upon treatment with β -glucocerebrosidase (GCase) activator, NCGC00188758 (56).

Copy number variations in *SNCA* locus are also linked to familial PD [duplication (5), triplication (4)]. Using a familial PD hiPSC with *SNCA* locus duplication, Prots *et al.* reported a significant increase in the level of 1% Triton X-100/1% NP-40/1% SDS-insoluble-and-8 M urea/5% SDS-soluble α -syn aggregates in the EB-derived PD neurons co-cultured with primary human cerebellar astrocytes, as compared to healthy controls (57). The authors performed sucrose density gradient centrifugation analysis to assess the composition of α -syn aggregates and revealed an increase in the presence of α -syn aggregation intermediates in the PD neurons (57). Other report exhibited the increased formation of filamentous α -syn aggregates and cell death in the 70-90 days old cortical neurons differentiated from a familial PD hiPSC with *SNCA* locus triplication, as compared to genetically corrected controls (58). In addition, Tagliafierro *et al.* described an increase in the number of punctate α -syn aggregates in the EB-derived 45-50 days old mDA neurons differentiated from a familial PD hiPSC with *SNCA* locus triplication compared to the controls (59). Moreover, the increment and the size of punctate α -syn aggregates were more augmented in >70 days old PD mDA neurons, as compared to 45-50 days old neurons (59). The authors have additionally shown an increase in the formation and size of diffused α -syn aggregates in >70 days old PD basal

forebrain cholinergic neurons (BFCNs), which are primarily affected in DLB, compared to 45-50 days old neurons (59). Mazzulli et al. reported the detection of thioflavin S-positive α -syn aggregates in the FP-derived 100 or 120 days old mDA neurons differentiated from a familial PD hiPSC with *SNCA* locus triplication (51, 56). In addition, the amount of pathogenic α -syn detected by Syn303 antibody was increased in the 1% Triton X-100-insoluble-and-2% SDS-soluble fraction of 55-330 days old PD mDA neurons carrying an *SNCA* locus triplication than healthy hiPSC-derived mDA neurons (51). Another report described the increased level of pS129- α -syn in the FP-derived 44-46 days old mDA neurons and revealed the increased susceptibility to neurotoxins in 34 days old mDA neurons, differentiated from a familial PD hiPSC with *SNCA* locus triplication compared to healthy hiPSCs (53).

Familial PD hiPSC-based model: LRRK2 mutations

Mutations in *LRRK2* (also known as *PARK8*) gene, which encodes leucine-rich repeat serine/threonine-protein kinase 2, lead to autosomal dominant PD (60). Even though an attempt was made to analyze numerous articles which attempted to recapitulate PD phenotypes using PD hiPSCs with *LRRK2* mutations, none of the reports provided solid evidence showing α -syn aggregation in patient-derived mDA neurons. Instead, one recently published paper reported an increase in α -syn puncta in 28 days old PD astrocytes with a point mutation in the *LRRK2* gene (c.[6055G>A];[=]/p.[Gly2019Ser];[=], also known as heterozygous G2019S), as compared to healthy astrocytes (61).

Familial PD hiPSC-based model: PRKN mutations

Mutations in *PRKN* (also known as *PARK2*) gene, which encodes E3 ubiquitin-protein ligase parkin, lead to autosomal recessive PD (60). Shaltouki et al. demonstrated the formation of

tentative α -syn aggregates in the EB-derived 28 days old mDA neurons differentiated from familial PD hiPSCs with various mutations in *PRKN* gene; i.e., p.[Arg42Pro];[=], p.[Arg275Trp];[=], p.[Arg42Pro];[EX3del], and p.[Asn52fs];[EX3_4del] (62). On the other hand, Chung et al. reported a significant increase in the level of 1% Triton X-100-insoluble-and-2% SDS-soluble α -syn aggregates in the FP-derived 60 days old mDA neurons differentiated from a PD hiPSC with same point mutations in both the *PRKN* alleles (c.[971delT];[971delT]/p.[Val324Alafs*111];[Val324Alafs*111], also known as homozygous V324fs), as compared to healthy controls (63). Furthermore, the researchers provided evidence of the dependency on the type of differentiation protocol utilized; the FP-derived PD mDA neurons recapitulated PD phenotypes *in vitro* while the neural rosette-derived PD mDA neurons (40) did not recapitulate these phenotypes (63).

Familial PD hiPSC-based model: PINK1 mutations

Mutations in *PINK1* (also known as *PARK6*) gene, which encodes serine/threonine-protein kinase PINK1 mitochondrial, lead to autosomal recessive PD (60). In the FP-derived 60 days old mDA neurons differentiated from a PD hiPSC with point mutations in the *PINK1* gene (c.[1366C>T];[1366C>T]/p.[Gln456Ter];[Gln456Ter], also known as homozygous Q456X), the level of 1% Triton X-100-insoluble-and-2% SDS-soluble α -syn aggregates was significantly increased compared to healthy controls; however, it was not observed in the neural rosette-derived PD mDA neurons (63).

Familial PD hiPSC-based model: ATP13A2 mutations

Mutations in *ATP13A2* (also known as *PARK9*) gene, which encodes cation-transporting ATPase 13A2, lead to autosomal recessive PD (60). Mazzulli et al. reported that the amount of 1% Triton X-100-insoluble-and-2% SDS-soluble α -syn was increased in the FP-derived 90

days old mDA neurons differentiated from a familial PD hiPSC with point mutations in *ATP13A2* gene (c.[3176T>C];[3253delC]/p.[Leu1059Arg];[Leu1085Trpfs*4], also known as heterozygous L1059R;L1085fs) compared to healthy control (56).

PD-related hiPSC-based model: GBA mutations

GBA (also known as *GBA1*) gene, which encodes lysosomal acid glucosylceramidase (also known as β -glucocerebrosidase or GCase), has a critical role in glycolipid metabolism. Loss-of-function mutations in the *GBA* gene cause lysosomal defects *via* accumulation of lipid substrates in the lysosome that results in autosomal recessive Gaucher disease (GD) (64). Moreover, mutations in the *GBA* gene are well-known to increase the risk of developing PD and DLB (65-70). Using a GD hiPSC with mutations in the *GBA* gene (c.[1226A>G];[84dupG]/p.[Asn409Ser];[Leu29Alafs*18], also known as heterozygous N409S; L29fs), Mazzulli et al reported the detection of thioflavin S-positive α -syn aggregates in the FP-derived 100 or 120 days old GD mDA neurons (51, 56). In addition, the authors demonstrated that the amount of pathogenic α -syn detected by Syn303 antibody was increased in the 1% Triton X-100-insoluble-and-2% SDS-soluble fraction of the 90 days old GD mDA neurons compared to healthy hiPSC-derived mDA neurons (51).

Groundbreaking researches suggested that α -syn exists as a helically folded tetramer in the physiological conditions and not in the form of natively unfolded monomer; the tetramer is rarely gets converted into the pathological aggregates (23, 24). A recent study has reported that the ratio of α -syn tetramers and related multimers, which resist aggregation, to monomers was reduced in the FP-derived 60-65 days old mDA neurons differentiated from a PD hiPSC with a point mutation in *GBA* gene (c.[1226A>G];[=]/p.[Asn409Ser];[=], also known as heterozygous N409S) compared to healthy iPSCs; indirectly revealing that the level of α -syn aggregates may be increased in the cells of the patient (71). The authors also

revealed an increase in the levels of 1% Triton X-100-insoluble-and-2% SDS-soluble α -syn aggregates and pS129- α -syn in the α -syn pre-formed fibril [α -PFFs (72)]-treated FP-derived 73 days old PD mDA neurons compared to healthy controls (71).

PERSPECTIVES

It is feasible to reproduce the molecular pathology of α -synucleinopathies without using any exogenous factors and by employing only hiPSC-based PD modeling system along with the patient's genetic background. However, only a handful of papers demonstrated success in recapitulating α -syn aggregation *in vitro*, among a large number of PD hiPSC-based models (**Table 1**). It is hypothesized that there might be three potential underlying causes of this problem: i) insufficient aging, ii) incomplete differentiation protocol, and iii) lack of environmental cues.

Even though hiPSCs were generated by reprogramming of somatic cells from aged PD patients, their ages seemed to be reset to embryonic ages during the reprogramming process (73-76). Moreover, hiPSC-derived neurons, such as human mDA neurons, are largely regarded as embryonic stage neurons (73-76). Therefore, resolving an aging issue and/or a maturation issue is necessary to model late-onset diseases, such as PD and DLB. Apparently, the progerin-induced aging method could be used as one of the possible solutions (77).

We are constantly attempting to improve mDA neuronal differentiation protocols for modeling PD more complete, beyond EB-derived, feeder-dependent, neural rosette-derived, and FP-derived methods (**Figure 1**). Very recently, the protocols to differentiate hPSCs or neuroepithelial stem cells into human midbrain organoids have been developed for the generation of more ideal human mDA neuronal models (78-80). These midbrain organoids

will serve as a completer and more important biologically relevant cell sources for PD modeling.

Environmental factors may cause PD along with genetic factors. Peng et al. demonstrated that environmental factors, such as neurotoxins, together with genetic mutations in PD in the same animal, synergistically accelerate age-related neurodegeneration (81). Similarly, only after treatment of α -PFFs, PD-relevant phenotypes including increased levels of detergent-insoluble α -syn aggregates and pS129- α -syn were detected in mDA neurons differentiated from PD hiPSC with a *GBA* mutation (p.N409S) (71). These results suggest that the addition of environmental factors to the PD iPSC models might be the key to reveal the hidden phenotypes.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grants funded by different governments of Korea (Ministry of Education, NRF-2017R1A6A3A03010524; Ministry of Science and ICT, NRF-2018R1C1B5045395) and by the research fund of Hanyang University (HY-2018). I sincerely apologize to colleagues whose work has not been cited in this review due to space limitations.

CONFLICTS OF INTEREST

The author declares no conflict of interest.

FIGURE LEGENDS

Figure 1. Derivation of human midbrain dopaminergic neurons from hPSC. (A) A protocol developed by Sonntag et al. for the generation of human mDA neurons *via* the neural rosette-isolation, from hESCs co-cultured with the MS-5 cells as a feeder (41). (B) A protocol developed by Swistowski et al. for the generation of expandable mDA progenitors and mDA neurons from hESCs *via* the embryonic body (EB)-formation and neural rosette-isolation (44). (C) A protocol developed by Kriks et al. for the generation of hPSC-derived mDA neurons *via* the floor plate (FP)-induction (47). AA, ascorbic acid. CHIR, CHIR99021. dbcAMP, dibutyryl-cyclic AMP. LDN, LDN193189. MS-5-Wnt1, Wnt1 transgenic MS-5 cells. PMP, purmorphamine. SB, SB431542.

Table 1. Selected reports showing the endogenous α -synuclein aggregation using PD hiPSC-derived cell models.

Genetic mutation	Tested model	Differentiation protocol (ref.)	Differentiation marker	Stimulus	Aggregate WB	Aggregate ICC	Cell death	Note	Ref.
Sporadic									
unknown	mDA	2D-based (45, 47)	n.d.	no	yes	yes	n.d.	increased detergent-insoluble α -syn aggregates at day 110; thioflavin S-positive α -syn aggregates formation at day 110; lysosomal defects at day 90	(51)
SNCA									
p.[Ala53Thr];[=]	mDA GABAergic GLUergic	EB-based (43, 45, 49) ~20% TH ⁺ ; ~25% GABA ⁺ ; ~20% VGLUT1 ⁺	FOXA2, NURR1, PITX3, TH, MAP2, GAD67, VGLUT1 (qRT-PCR); TH, GABA, VGLUT1 (ICC)	no	n.d.	yes	yes	detection of thioflavin S-positive and proteinase K-resistant α -syn aggregates at day 50; increased pS129- α -syn at day 50; decreased neurite length at day 50	(54)
p.[Ala53Thr];[=]	mDA	2D-based (45, 47) ~73% TH ⁺ /GIRK2 ⁺	OTX2, LMX1A, FOXA2, NURR1, TH, GIRK2 (ICC)	no	n.d.	yes	no	increased thioflavin T-positive or S129-phosphorylated α -syn aggregates formation and ROS production than genetically corrected controls at day 35	(55)
				paraquat	n.d.	n.d.	yes	increased apoptosis than genetically corrected controls at day 35	
				maneb	n.d.	n.d.	yes	increased apoptosis than genetically corrected controls at day 35	
				rotenone	n.d.	n.d.	yes	increased apoptosis than genetically corrected controls at day 35	
p.[Ala53Thr];[=]	mDA	2D-based (45, 47)	n.d.	no	n.d.	yes	n.d.	detection of thioflavin S-positive α -syn aggregates at day 90; reduced aggregates formation by 758 treatment at day 90	(56)
duplication	neuron	EB-based (82)	n.d.	no	yes	n.d.	n.d.	neural rosette-derived neurons co-cultured with astrocytes; increased detergent-insoluble α -syn aggregates; increased presence of α -syn aggregation intermediates	(57)
triplication	cortical	2D-based (45) ~70% neurons activated by glutamate	Glutamate response (Ca ²⁺ imaging)	no	n.d.	yes	yes	increased filamentous α -syn aggregates formation and cell death than genetically corrected controls at day 70-90; increased NADH redox index than control at day 70-90	(58)
triplication	mDA	EB-based (53) ~28% TH ⁺ /TUBB3 ⁺ (83)	FOXA2, TH (qRT-PCR) FOXA2, TH (ICC)	no	n.d.	yes	n.d.	neural rosette-derived mDA; increased number and size of punctate α -syn aggregates at day >71 than at day 45-50	(59)

Genetic mutation	Tested model	Differentiation protocol (ref.)	Differentiation marker	Stimulus	Aggregate WB ICC		Cell death	Note	Ref.
	BFCN	EB-based (84, 85) ~36% VCHT ⁺ /TUBB3 ⁺ (83)	<i>CHAT</i> (qRT-PCR) <i>CHAT</i> (ICC)	no	n.d.	yes	n.d.	neural rosette-derived BFCN; increased number and size of diffused α -syn aggregates at day >71 than at day 45-50	
triplication	mDA	2D-based (45, 47) ~70% TH ⁺ /FOXA2 ⁺	LMX1A, FOXA2, TH (ICC)	no	yes	yes	n.d.	increased detergent-insoluble α -syn aggregates at day 55-330; thioflavin S-positive α -syn aggregates formation at day 100 or 120; increased low expressing TH cells at day 330; lysosomal defects at day 180 or 330; reduced aggregates formation by 758 treatment at day 120	(51, 56)
LRRK2									
p.[Gly2019Ser] :[=]	astrocyte	3D-based (86) ~95% GFAP ⁺	<i>AQP4</i> , <i>GFAP</i> (qRT-PCR); <i>GFAP</i> , S100 β , <i>GLT1</i> (ICC)	no	n.d.	yes	n.d.	increased α -syn puncta area at day 28; transmitting α -syn to mDA neurons during 28 days co-culture	(61)
PRKN									
p.[Arg42Pro] :[=]	mDA	EB-based (44) ~7% TH ⁺	FOXA2, TH (ICC)	no	u.c.	u.c.	n.d.	decreased mDA neuronal differentiation than healthy control (~22% TH ⁺) at day 28	(62)
p.[Arg275Trp] :[=]	mDA	EB-based (44) ~15% TH ⁺	FOXA2, TH (ICC)	no	u.c.	u.c.	n.d.	decreased mDA neuronal differentiation than healthy control (~22% TH ⁺) at day 28	(62)
p.[Arg42Pro] :[EX3del]	mDA	EB-based (44) ~7% TH ⁺	FOXA2, TH (ICC)	no	u.c.	u.c.	n.d.	decreased mDA neuronal differentiation than healthy control (~22% TH ⁺) at day 28	(62)
p.[Asn52fs] :[EX3_4del]	mDA	EB-based (44) ~7% TH ⁺	FOXA2, TH (ICC)	no	u.c.	u.c.	n.d.	decreased mDA neuronal differentiation than healthy control (~22% TH ⁺) at day 28	(62)
p.[Val324fs] :[Val324fs]	mDA	2D-based (45, 47) ~70% TH ⁺	LMX1A, FOXA2, NURR1, TH (ICC)	no	yes	u.c.	n.d.	increased Triton X-100-insoluble α -syn aggregates at day 60; increased intracellular dopamine level; increased susceptibility to mitochondria toxin at day 60	(63)
PINK1									
p.[Gln456Ter] :[Gln456Ter]	mDA	2D-based (45, 47) ~75% TH ⁺	LMX1A, FOXA2, NURR1, TH (ICC)	no	yes	u.c.	n.d.	increased Triton X-100-insoluble α -syn aggregates at day 60; increased susceptibility to mitochondria toxin at day 60	(63)
ATP13A2									
p.[Leu1059Arg] :[Leu1085fs]	mDA	2D-based (45, 47) ~60% TH ⁺ /FOXA2 ⁺	FOXA2, TH (ICC)	no	yes	n.d.	n.d.	increased detergent-insoluble α -syn aggregates at day 90; lysosomal defects at day 90	(56)

Genetic mutation	Tested model	Differentiation protocol (ref.)	Differentiation marker	Stimulus	Aggregate		Cell death	Note	Ref.
GBA									
p.[Asn409Ser];[Leu29fs]	mDA	2D-based (45, 47) ~60% TH ⁺ /FOXA2 ⁺	LMX1A, FOXA2, TH (ICC)	no	yes	yes	n.d.	increased detergent-insoluble α-syn aggregates at day 90; thioflavin S-positive α-syn aggregates formation at day 100 or 120; increased low expressing TH cells at day 330; lysosomal defects at day 110, 120 or 180; reduced aggregates formation by 758 treatment at day 120	(51, 56)
p.[Asn409Ser];[=]	mDA	2D-based (45, 47) ~75% TH ⁺	FOXA2, NURR1, TH (qRT-PCR); FOXA2, PITX3, TH (ICC)	no	u.c.	n.d.	no	reduced ratio of tetramers and related multimers, which resist aggregation, to monomers at day 60-65 increased detergent-insoluble α-syn aggregates at day 73; increased pS129-α-syn at day 73; increased cell death at day 73 or 79	(71)
				α-PFF	yes	n.d.	yes		

2D, monolayer differentiation. 3D, neurosphere differentiation. 758, NCGC00188758. α-PFF, α-syn pre-formed fibril (72). BFCN, basal forebrain cholinergic neuron. cortical, cortical neuron. del, deletion. EB, embryonic body differentiation. EX, exon. fs, frameshift. GABAergic, GABAergic neuron. GLUergic, glutamatergic neuron. ICC, confirmed by immunocytochemistry. mDA, midbrain dopaminergic neuron. n.d., not determined. NPC, neuronal precursor cell. p., protein sequence. qRT-PCR, quantitative real-time PCR. u.c., unclear. WB, confirmed by western blotting.

REFERENCES

1. Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci* 22, 123-144
2. Dauer W and Przedborski S (2003) Parkinson's disease: mechanisms and models. *Neuron* 39, 889-909
3. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276, 2045-2047
4. Singleton AB, Farrer M, Johnson J et al (2003) alpha-Synuclein locus triplication causes Parkinson's disease. *Science* 302, 841
5. Chartier-Harlin MC, Kachergus J, Roumier C et al (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. *Lancet* 364, 1167-1169
6. Lee VM and Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. *Neuron* 52, 33-38
7. Fujiwara H, Hasegawa M, Dohmae N et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4, 160-164
8. Jackson-Lewis V, Blesa J and Przedborski S (2012) Animal models of Parkinson's disease. *Parkinsonism Relat Disord* 18 Suppl 1, S183-185
9. Koprach JB, Kalia LV and Brotchie JM (2017) Animal models of alpha-synucleinopathy for Parkinson disease drug development. *Nat Rev Neurosci* 18, 515-529
10. Brennand KJ, Simone A, Jou J et al (2011) Modelling schizophrenia using human induced pluripotent stem cells. *Nature* 473, 221-225
11. Dimos JT, Rodolfa KT, Niakan KK et al (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. *Science* 321, 1218-1221
12. Laflamme MA, Chen KY, Naumova AV et al (2007) Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. *Nat*

Biotechnol 25, 1015-1024

13. Li XJ, Du ZW, Zarnowska ED et al (2005) Specification of motoneurons from human embryonic stem cells. *Nat Biotechnol* 23, 215-221
14. Maroof AM, Brown K, Shi SH, Studer L and Anderson SA (2010) Prospective isolation of cortical interneuron precursors from mouse embryonic stem cells. *J Neurosci* 30, 4667-4675
15. Cunningham M, Cho JH, Leung A et al (2014) hPSC-derived maturing GABAergic interneurons ameliorate seizures and abnormal behavior in epileptic mice. *Cell Stem Cell* 15, 559-573
16. Joseph NM and Morrison SJ (2005) Toward an understanding of the physiological function of Mammalian stem cells. *Dev Cell* 9, 173-183
17. Saha K and Jaenisch R (2009) Technical challenges in using human induced pluripotent stem cells to model disease. *Cell Stem Cell* 5, 584-595
18. Li H, Jiang H, Zhang B and Feng J (2018) Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. *J Parkinsons Dis* 8, 479-493
19. Sison SL, Vermilyea SC, Emborg ME and Ebert AD (2018) Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes. *Curr Neurol Neurosci Rep* 18, 84
20. Ueda K, Fukushima H, Masliah E et al (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. *Proc Natl Acad Sci U S A* 90, 11282-11286
21. Weinreb PH, Zhen W, Poon AW, Conway KA and Lansbury PT, Jr. (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. *Biochemistry* 35, 13709-13715
22. Davidson WS, Jonas A, Clayton DF and George JM (1998) Stabilization of alpha-synuclein

- secondary structure upon binding to synthetic membranes. *J Biol Chem* 273, 9443-9449
23. Bartels T, Choi JG and Selkoe DJ (2011) alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. *Nature* 477, 107-110
24. Wang W, Perovic I, Chittuluru J et al (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. *Proc Natl Acad Sci U S A* 108, 17797-17802
25. Dettmer U, Newman AJ, Soldner F et al (2015) Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. *Nat Commun* 6, 7314
26. Tong J, Wong H, Guttman M et al (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. *Brain* 133, 172-188
27. Winklhofer KF, Tatzelt J and Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. *EMBO J* 27, 336-349
28. McCann H, Stevens CH, Cartwright H and Halliday GM (2014) alpha-Synucleinopathy phenotypes. *Parkinsonism Relat Disord* 20 Suppl 1, S62-67
29. Savica R, Grossardt BR, Bower JH, Ahlskog JE and Rocca WA (2013) Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. *JAMA Neurol* 70, 859-866
30. Oueslati A, Fournier M and Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. *Prog Brain Res* 183, 115-145
31. Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. *J Biol Chem* 281, 29739-29752
32. Chen L and Feany MB (2005) Alpha-synuclein phosphorylation controls neurotoxicity and

- inclusion formation in a *Drosophila* model of Parkinson disease. *Nat Neurosci* 8, 657-663
33. Yamada M, Iwatsubo T, Mizuno Y and Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. *J Neurochem* 91, 451-461
34. Takahashi M, Kanuka H, Fujiwara H et al (2003) Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic *Drosophila*. *Neurosci Lett* 336, 155-158
35. Oueslati A (2016) Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? *J Parkinsons Dis* 6, 39-51
36. Tenreiro S, Eckermann K and Outeiro TF (2014) Protein phosphorylation in neurodegeneration: friend or foe? *Front Mol Neurosci* 7, 42
37. Arenas E, Denham M and Villaescusa JC (2015) How to make a midbrain dopaminergic neuron. *Development* 142, 1918-1936
38. Park CH, Minn YK, Lee JY et al (2005) In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. *J Neurochem* 92, 1265-1276
39. Zeng X, Cai J, Chen J et al (2004) Dopaminergic differentiation of human embryonic stem cells. *Stem Cells* 22, 925-940
40. Perrier AL, Tabar V, Barberi T et al (2004) Derivation of midbrain dopamine neurons from human embryonic stem cells. *Proc Natl Acad Sci U S A* 101, 12543-12548
41. Sonntag KC, Pruszak J, Yoshizaki T, van Arensbergen J, Sanchez-Pernaute R and Isacson O (2007) Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. *Stem Cells* 25, 411-418
42. Roy NS, Cleren C, Singh SK, Yang L, Beal MF and Goldman SA (2006) Functional

- engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. *Nat Med* 12, 1259-1268
43. Kim BK, Kim SE, Shim JH et al (2006) Neurogenic effect of vascular endothelial growth factor during germ layer formation of human embryonic stem cells. *FEBS Lett* 580, 5869-5874
44. Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS and Zeng X (2009) Xeno-free defined conditions for culture of human embryonic stem cells, neural stem cells and dopaminergic neurons derived from them. *PLoS One* 4, e6233
45. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M and Studer L (2009) Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol* 27, 275-280
46. Fasano CA, Chambers SM, Lee G, Tomishima MJ and Studer L (2010) Efficient derivation of functional floor plate tissue from human embryonic stem cells. *Cell Stem Cell* 6, 336-347
47. Kriks S, Shim JW, Piao J et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* 480, 547-551
48. Chambers SM, Qi Y, Mica Y et al (2012) Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. *Nat Biotechnol* 30, 715-720
49. Soldner F, Hockemeyer D, Beard C et al (2009) Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. *Cell* 136, 964-977
50. Baba M, Nakajo S, Tu PH et al (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *Am J Pathol* 152, 879-884
51. Mazzulli JR, Zunke F, Isacson O, Studer L and Krainc D (2016) alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain

- synucleinopathy models. *Proc Natl Acad Sci U S A* 113, 1931-1936
52. Giasson BI, Duda JE, Murray IV et al (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. *Science* 290, 985-989
53. Lin L, Goke J, Cukuroglu E, Dranias MR, VanDongen AM and Stanton LW (2016) Molecular Features Underlying Neurodegeneration Identified through In Vitro Modeling of Genetically Diverse Parkinson's Disease Patients. *Cell Rep* 15, 2411-2426
54. Kouroupi G, Taoufik E, Vlachos IS et al (2017) Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. *Proc Natl Acad Sci U S A* 114, E3679-E3688
55. Ryan SD, Dolatabadi N, Chan SF et al (2013) Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. *Cell* 155, 1351-1364
56. Mazzulli JR, Zunke F, Tsunemi T et al (2016) Activation of beta-Glucocerebrosidase Reduces Pathological alpha-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. *J Neurosci* 36, 7693-7706
57. Prots I, Grosch J, Brazdis RM et al (2018) alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. *Proc Natl Acad Sci U S A* 115, 7813-7818
58. Ludtmann MHR, Angelova PR, Horrocks MH et al (2018) alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease. *Nat Commun* 9, 2293
59. Tagliafierro L, Zamora ME and Chiba-Falek O (2019) Multiplication of the SNCA locus exacerbates neuronal nuclear aging. *Hum Mol Genet* 28, 407-421
60. Klein C and Westenberger A (2012) Genetics of Parkinson's disease. *Cold Spring Harb*

61. di Domenico A, Carola G, Calatayud C et al (2019) Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. *Stem Cell Reports* 12, 213-229
62. Shaltouki A, Sivapatham R, Pei Y et al (2015) Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. *Stem Cell Reports* 4, 847-859
63. Chung SY, Kishinevsky S, Mazzulli JR et al (2016) Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and alpha-Synuclein Accumulation. *Stem Cell Reports* 7, 664-677
64. Hruska KS, LaMarca ME, Scott CR and Sidransky E (2008) Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). *Hum Mutat* 29, 567-583
65. Nalls MA, Duran R, Lopez G et al (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurol* 70, 727-735
66. Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med* 361, 1651-1661
67. Eblan MJ, Walker JM and Sidransky E (2005) The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. *N Engl J Med* 352, 728-731; author reply 728-731
68. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A and Sidransky E (2004) Parkinsonism among Gaucher disease carriers. *J Med Genet* 41, 937-940
69. Halperin A, Elstein D and Zimran A (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. *Blood Cells Mol Dis* 36, 426-428
70. Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME and Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. *Mol Genet Metab* 81, 70-73

71. Kim S, Yun SP, Lee S et al (2018) GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers. *Proc Natl Acad Sci U S A* 115, 798-803
72. Luk KC, Song C, O'Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. *Proc Natl Acad Sci U S A* 106, 20051-20056
73. Soria-Valles C and Lopez-Otin C (2016) iPSCs: On the Road to Reprogramming Aging. *Trends Mol Med* 22, 713-724
74. Zeltner N and Studer L (2015) Pluripotent stem cell-based disease modeling: current hurdles and future promise. *Curr Opin Cell Biol* 37, 102-110
75. Vera E and Studer L (2015) When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease. *Development* 142, 3085-3089
76. Studer L, Vera E and Cornacchia D (2015) Programming and Reprogramming Cellular Age in the Era of Induced Pluripotency. *Cell Stem Cell* 16, 591-600
77. Miller JD, Ganat YM, Kishinevsky S et al (2013) Human iPSC-based modeling of late-onset disease via progerin-induced aging. *Cell Stem Cell* 13, 691-705
78. Bolognin S, Fossepre M, Qing X et al (2019) 3D Cultures of Parkinson's Disease-Specific Dopaminergic Neurons for High Content Phenotyping and Drug Testing. *Adv Sci (Weinh)* 6, 1800927
79. Jo J, Xiao Y, Sun AX et al (2016) Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. *Cell Stem Cell* 19, 248-257
80. Monzel AS, Smits LM, Hemmer K et al (2017) Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells. *Stem Cell Reports* 8, 1144-1154
81. Peng J, Oo ML and Andersen JK (2010) Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration. *J*

Neurochem 115, 1363-1373

82. Havlicek S, Kohl Z, Mishra HK et al (2014) Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients' neurons. *Hum Mol Genet* 23, 2527-2541
83. Tagliafierro L, Glenn OC, Zamora ME et al (2017) Genetic analysis of alpha-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. *Alzheimers Dement* 13, 1237-1250
84. Hu Y, Qu ZY, Cao SY et al (2016) Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. *J Neurosci Methods* 266, 42-49
85. Crompton LA, Byrne ML, Taylor H et al (2013) Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling. *Stem Cell Res* 11, 1206-1221
86. Serio A, Bilican B, Barmada SJ et al (2013) Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. *Proc Natl Acad Sci U S A* 110, 4697-4702

